Dementia research has become increasingly focused on the prodromal stages of Alzheimer's disease (AD). Elucidating the mechanisms of disease pathogenesis and the reliable identification of people in early stages of cognitive decline will be critical to the development of efficacious therapies for AD. Recently, a clinical entity termed mild cognitive impairment (MCI) has been recognized as a transitional state between the cognitive changes seen in normal aging and AD. The prevalence of MCI is more than double that of dementia and in many cases MCI may be prodromal AD. Therefore, MCI is a suitable condition for exploring the neurobiology underlying AD pathogenesis. There is a paucity of data on pathological and biological markers that distinguish individuals with MCI from healthy aged individuals. To investigate pathobiological markers for MCI, we will employ a novel two-tiered, discovery-based proteomics approach. First, we will use two-dimensional gel electrophoresis (2DGE) and liquid chromatography-tandem mass spectrometry (LCMS/ MS) to identify specific alterations in protein levels in the entorhinal cortex (EC) of subjects with no cognitive impairment (NCI), MCI, or early stage/mild AD. The EC is the initial site of degeneration in MCI and is an ideal area to explore MCI pathogenesis. Second, we will use new surface-enhanced laser desorption/ionization-time of flight MS (SELDI-TOF MS) protein chip technology to evaluate the changes in the cerebrospinal fluid (CSF) of these same individuals. Both tissue and fluid samples will be obtained from our ongoing NIA-funded longitudinal study of aging and AD, the Religious Orders Study (ROS). The proposed studies will hopefully lead to the discovery of new proteins involved in the pathogenesis of AD and new biomarkers for the timely diagnosis of persons in the earliest stages of this devastating disease. Both of these factors will be critical for the development of neuroprotective strategies for slowing or preventing cognitive decline in the elderly.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AG026032-01
Application #
6906336
Study Section
Clinical Neuroscience and Disease Study Section (CND)
Program Officer
Snyder, Stephen D
Project Start
2005-08-15
Project End
2007-07-31
Budget Start
2005-08-15
Budget End
2006-07-31
Support Year
1
Fiscal Year
2005
Total Cost
$157,250
Indirect Cost
Name
Rush University Medical Center
Department
Neurosciences
Type
Schools of Medicine
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Counts, Scott E; Mufson, Elliott J (2017) Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimer's Disease. Cell Transplant 26:693-702
Counts, Scott E; Ikonomovic, Milos D; Mercado, Natosha et al. (2017) Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics 14:35-53
Mufson, Elliott J; Ikonomovic, Milos D; Counts, Scott E et al. (2016) Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav Brain Res 311:54-69
Counts, Scott E; He, Bin; Prout, John G et al. (2016) Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. Curr Alzheimer Res 13:800-8
Counts, Scott E; Mufson, Elliott J (2010) PUTATIVE CSF PROTEIN BIOMARKER CANDIDATES FOR AMNESTIC MILD COGNITIVE IMPAIRMENT. Transl Neurosci 1:2-8
Counts, Scott E; Mufson, Elliott J (2010) Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J Neurochem 113:649-60
Counts, Scott E; He, Bin; Che, Shaoli et al. (2009) Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease. J Alzheimers Dis 18:885-96
Counts, Scott E; He, Bin; Che, Shaoli et al. (2008) Galanin hyperinnervation upregulates choline acetyltransferase expression in cholinergic basal forebrain neurons in Alzheimer's disease. Neurodegener Dis 5:228-31
Mufson, Elliott J; Counts, Scott E; Perez, Sylvia E et al. (2008) Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 8:1703-18
Counts, S E; Perez, S E; Mufson, E J (2008) Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective? Cell Mol Life Sci 65:1842-53

Showing the most recent 10 out of 17 publications